Key Points
- Tonix Pharmaceuticals director Richard Newcomb Stillwell bought 5,000 shares on June 8 at an average price of $11.65, a purchase worth $58,250. After the transaction, he owned 5,000 shares.
- TNXP shares have been under pressure, recently opening at $11.46 versus 50-day and 200-day moving averages of $13.17 and $15.03, respectively. The stock also sits far below its 52-week high of $69.97.
- Analysts remain mixed on the stock, with ratings ranging from sell to strong buy and a consensus “Moderate Buy” price target of $22.00. The company also recently posted a quarterly loss that missed EPS estimates, though revenue topped expectations.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) Director Richard Newcomb Stillwell purchased 5,000 shares of Tonix Pharmaceuticals stock in a transaction dated Monday, June 8th. The stock was acquired at an average price of $11.65 per share, for a total transaction of $58,250.00. Following the completion of the acquisition, the director owned 5,000 shares of the company's stock, valued at approximately $58,250. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Tonix Pharmaceuticals Stock Performance
Shares of NASDAQ TNXP opened at $11.46 on Wednesday. The business's 50 day moving average price is $13.17 and its 200-day moving average price is $15.03. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $10.87 and a fifty-two week high of $69.97. The company has a market cap of $182.67 million, a price-to-earnings ratio of -0.80 and a beta of 1.67.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($2.93) earnings per share for the quarter, missing the consensus estimate of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative return on equity of 67.65% and a negative net margin of 839.52%.The business had revenue of $6.88 million during the quarter, compared to analysts' expectations of $6.13 million. Sell-side analysts predict that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current year.
Analysts Set New Price Targets
Several research analysts recently issued reports on the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a research note on Monday, April 20th. TD Cowen raised Tonix Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, May 5th. Finally, Wall Street Zen cut Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Sunday, April 26th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $22.00.
View Our Latest Stock Analysis on TNXP
Institutional Investors Weigh In On Tonix Pharmaceuticals
Hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc purchased a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth $25,000. Russell Investments Group Ltd. purchased a new stake in shares of Tonix Pharmaceuticals during the 3rd quarter worth $29,000. State of Wyoming purchased a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $27,000. BNP Paribas Financial Markets purchased a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth $65,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth $104,000. 82.26% of the stock is currently owned by hedge funds and other institutional investors.
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company's pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.
Among Tonix's lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
